
|Articles|April 15, 2003
Anti-VEGF treatment shows promise in preliminary trials
Boston-Multiple intravitreal injections of rhuFab V2 (Genentech Inc., San Francisco) are well-tolerated and appear to have favorable biologic activity for the treatment of exudative age-related macular degeneration (AMD), said Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston and the Center for Eye Research, principal investigator for that trial.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
AAO 2025: Glaucoma laser surgery with Joel S. Schuman, MD, FACS
3
News from Orlando: AAO 2025 highlights research across all areas of eyecare
4
AAO 2025: Which lens to consider in patients with pseudoexfoliation
5